GnRHope Therapeutics aims to launch to market a pulsatile gonadotropin-releasing hormone (GnRH) therapy for patients suffering from cognition deficits (due to chromosomal abnormalities (Prader-Willi, Down Syndrom), or age-related cognitive decline), in order to mobilize their cognitive reserve and thus improve or maintain intellectual performance. In addition, GnRHope Therapeutics has shown that GnRH delivery plays a role in energy metabolism, regulating weight gain and thus acting against obesity.
Would you like to edit the information on your profile page?
Oops! We could not locate your form.